Cantabio Pharmaceuticals Inc. (CTBO)

[JMMatthews]

Also new company director: http://ih.advfn.com/p.php?pid=nmona&article=78462610

On October 12, 2018, our board of directors appointed Dr. Max Zhu as a director of our company.

Dr. Max Zhu, age 36, has been a research scientist and Head of Computer-Aided Drug Design at Cantabio Pharmaceuticals Inc. since 2015. His areas of responsibility expanded in late 2017 to include business development activities for the company in Asia. Dr. Zhu has been a key player in the advancement of Cantabio’s therapeutic programs. More recently he has become more involved in developing business and investor relationships for the company in Asia, where he is able to bring his network of contacts both in research and the investment community to help with the commercial development of the company. Prior to working with Cantabio, Dr. Zhu has worked as a scientist at VITA-Genes and also as Technology Officer at Vitargent Biotechnologies, both biotech companies based in the Hong Kong Science Park. In these roles he developed knowledge and knowhow in biomedical innovations and R&D commercialization in the region. At both companies he was also involved in business development and strategies as well as sales and marketing, gaining experiences as a biotech entrepreneur in the greater China area.

Dr. Zhu obtained his PhD at the University of Cambridge researching Alzheimer’s Disease in 2013. His thesis focused on computational studies of the Abeta peptide and amyloid which led to the discovery of a set of compounds which could become potential drug leads for Alzheimer’s disease. Dr. Zhu’s research required the use of computer science, AI, genome and protein structure analysis, computational biology and chemistry, applying the combination of different skillsets and knowledge in a multi-disciplinary biomedical research environment, and he has been both lead and co-author on a number of peer reviewed articles in this area.

Dr. Zhu has entered into convertible loan agreements with Cantabio as previously disclosed with the SEC.

CTBO $$$